

Noboru Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2771708/publications.pdf>

Version: 2024-02-01

106
papers

4,677
citations

134610

34
h-index

124990

64
g-index

108
all docs

108
docs citations

108
times ranked

6137
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, 52, 53-64.	0.6	0
2	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia. Clinical Cancer Research, 2022, 28, 870-881.	3.2	32
3	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. European Journal of Cancer, 2022, 162, 1-10.	1.3	14
4	Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 1783-1791.	3.2	3
5	Practical consideration for successful sequential tumor biopsies in first-in-human trials. Investigational New Drugs, 2022, 40, 841-849.	1.2	0
6	Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. Clinical Lung Cancer, 2022, 23, 386-392.	1.1	15
7	Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. Clinical Lung Cancer, 2022, 23, 477-486.	1.1	10
8	Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. Thoracic Cancer, 2022, 13, 2192-2200.	0.8	5
9	Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 53-64.	1.1	6
10	Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Journal of Cancer Research and Clinical Oncology, 2021, 147, 245-251.	1.2	47
11	Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Japanese Journal of Clinical Oncology, 2021, 51, 1757-1760.	0.6	5
12	The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Japanese Journal of Clinical Oncology, 2021, 51, 693-699.	0.6	4
13	First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer Science, 2021, 112, 1514-1523.	1.7	6
14	A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors. Investigational New Drugs, 2021, 39, 1036-1046.	1.2	11
15	First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-1-Positive Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3905-3915.	3.2	37
16	Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science, 2021, 112, 2361-2370.	1.7	33
17	Impact of ALK Inhibitors in Patients With <i>ALK</i> -Rearranged Nonlung Solid Tumors. JCO Precision Oncology, 2021, 5, 756-766.	1.5	16
18	Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.. Journal of Clinical Oncology, 2021, 39, 9044-9044.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 40-45.	0.9	15
20	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	1.7	17
21	Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. <i>Npj Precision Oncology</i> , 2021, 5, 66.	2.3	19
22	Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. <i>Cancer Science</i> , 2021, 112, 3911-3917.	1.7	17
23	Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2021, 22, 282-291.e6.	1.1	12
24	Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	5
25	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5771-5780.	3.2	15
26	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2078-2090.	0.5	29
27	TAS-116 (Pimipespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). <i>Clinical Cancer Research</i> , 2021, 27, 6709-6715.	3.2	20
28	A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456.	1.2	16
29	Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. <i>Investigational New Drugs</i> , 2020, 38, 468-477.	1.2	17
30	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 449-459.	1.1	1
31	Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 242-249.	5.1	117
32	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 140, 28-36.	1.3	17
33	Phase II trial of Sâ€1 treatment as palliativeâ€intent chemotherapy for previously treated advanced thymic carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7418-7427.	1.3	13
34	Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e000653.	2.0	5
35	Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 843-850.	5.1	124
36	MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 596-605.	2.3	20

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1724-1738.	1.7	20
38	First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. <i>Cancer Science</i> , 2020, 111, 571-579.	1.7	16
39	CD200 ⁺ tumor-infiltrating immune cells and CD204 ⁺ M2 macrophages are associated with prognosis in thymic carcinoma. <i>Cancer Science</i> , 2020, 111, 1921-1932.	1.7	28
40	Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1933-1942.	1.7	13
41	Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015. <i>Investigational New Drugs</i> , 2019, 37, 166-174.	1.2	4
42	Association of CD204 ⁺ macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT. <i>European Journal of Haematology</i> , 2019, 103, 578-587.	1.1	3
43	A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6614-6622.	3.2	106
44	First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 531-540.	1.9	49
45	Feasibility of genomic profiling with next-generation sequencing using specimens obtained by image-guided percutaneous needle biopsy. <i>Upsala Journal of Medical Sciences</i> , 2019, 124, 119-124.	0.4	10
46	Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study. <i>Journal of Thoracic Disease</i> , 2019, 11, 1347-1354.	0.6	3
47	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	1.7	238
48	Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (J025567): Updated Safety Results. <i>Drug Safety</i> , 2018, 41, 229-237.	1.4	48
49	A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. <i>International Journal of Clinical Oncology</i> , 2018, 23, 382-388.	1.0	53
50	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411.	0.8	230
51	Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. <i>ESMO Open</i> , 2018, 3, e000399.	2.0	6
52	Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. <i>Cancer Science</i> , 2018, 109, 3583-3590.	1.7	118
53	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1,0,784314,rgBT/One	1.7	38
54	An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 685-694.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 950-952.	0.6	10
56	Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience. <i>Investigational New Drugs</i> , 2017, 35, 392-396.	1.2	2
57	Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan. <i>International Journal of Clinical Oncology</i> , 2017, 22, 780-785.	1.0	0
58	Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK -Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, e251-e258.	1.1	15
59	Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 207-216.	1.2	70
60	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 42-50.	5.2	252
61	Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 70-78.	1.0	8
62	Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 37-46.	1.2	26
63	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 596-603.	1.2	43
64	Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. <i>Lung Cancer</i> , 2016, 93, 77-81.	0.9	13
65	A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. <i>Journal of Clinical Oncology</i> , 2016, 34, 10111-10111.	0.8	9
66	Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. <i>BMC Research Notes</i> , 2015, 8, 800.	0.6	38
67	A phase I study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1063-1072.	1.1	25
68	Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization. <i>Journal of Clinical Oncology</i> , 2015, 33, 2051-2061.	0.8	9
69	A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 229-231.	0.6	7
70	A phase I study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1153-1161.	1.1	48
71	Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 713-721.	1.1	2
72	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 385-390.	1.1	115

#	ARTICLE	IF	CITATIONS
73	Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 511-516.	1.1	37
74	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1236-1244.	5.1	678
75	Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. <i>BMC Cancer</i> , 2014, 14, 530.	1.1	37
76	A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 15-23.	1.1	37
77	Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 577-584.	1.1	26
78	Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1645-1655.	1.1	14
79	Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. <i>Investigational New Drugs</i> , 2013, 31, 677-684.	1.2	34
80	A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2013, 82, 109-114.	0.9	84
81	A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 559-565.	1.1	7
82	Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1099-1105.	1.1	21
83	An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1477-1486.	1.1	21
84	A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2012, 103, 504-509.	1.7	66
85	Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1101-1109.	1.1	14
86	Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1119-1128.	1.1	11
87	Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 2528-2537.	3.2	137
88	Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 935-943.	1.1	17
89	A Phase 1 Clinical Study of Temozolomide (CC-779) in Japanese Patients with Advanced Solid Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 732-738.	0.6	23
90	Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 404-411.	0.6	37

#	ARTICLE	IF	CITATIONS
91	Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 260-266.	0.6	57
92	Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN [®]), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1165-1172.	1.1	46
93	A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 79-88.	1.1	13
94	Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. <i>Cancer Science</i> , 2009, 100, 1728-1734.	1.7	39
95	Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 489-496.	1.1	75
96	Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 751-758.	1.1	26
97	Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4751-4757.	3.2	77
98	Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 497-504.	0.7	259
99	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 1002-1009.	0.5	86
100	Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 173-182.	1.1	20
101	Phase I Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 768-774.	0.6	22
102	Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. <i>Cancer Science</i> , 2005, 96, 721-728.	1.7	32
103	Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous Cortisol. <i>Journal of Clinical Oncology</i> , 2005, 23, 1061-1069.	0.8	75
104	Phase I and Pharmacokinetic Study of KRN5500, a Spicamycin Derivative, for Patients with Advanced Solid Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 302-308.	0.6	8
105	Phase I and Pharmacokinetic Study of a New Taxoid, RPR 109881A, Given as a 1-Hour Intravenous Infusion in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 3164-3171.	0.8	43
106	Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol. <i>Journal of Clinical Oncology</i> , 2000, 18, 2301-2308.	0.8	93